Class / Patent application number | Description | Number of patent applications / Date published |
514722000 | Acyclic | 46 |
20080234389 | FLUOROPOLYMER-BASED EMULSIONS FOR THE INTRAVENOUS DELIVERY OF FLUORINATED VOLATILE ANESTHETICS - The present invention provides therapeutic formulations, including therapeutic emulsions and nanoemulsions, and related methods for the delivery of fluorinated therapeutic compounds, including an important class of low boiling point perfluorinated and/or perhalogenated volatile anesthetics. Emulsion-based fluorinated volatile anesthetic formulations compatible with intravenous administration are provided that are capable of delivering and releasing amounts of fluorinated volatile anesthetic compounds effective for inducing and maintaining anesthesia in patients. Intravenous delivery of the present emulsion-based fluorinated volatile anesthetic formulations permits anesthetic levels in a patient to be selectively adjusted very rapidly and accurately without the need to hyperventilate patients and without the use of irritating agents. | 09-25-2008 |
20110039944 | VOLATILE ANESTHETIC COMPOSITIONS COMPRISING EXTRACTIVE SOLVENTS FOR REGIONAL ANESTHESIA AND/OR PAIN RELIEF - The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic dissolved in a solution comprising an extractive solvent, e.g., DMSO or NMP, in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered as a regional anesthesia to a subject to anesthetize a portion the subject prior to a surgery, hi certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, or mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated. | 02-17-2011 |
20110269843 | METHODS FOR DELIVERING VOLATILE ANESTHETICS FOR REGIONAL ANESTHESIA AND/OR PAIN RELIEF - The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated. | 11-03-2011 |
20110306676 | Method and Medicament for Pain Management - The present invention relates to a method and an apparatus for treating pain in a patient, such as a veterinary patient. The method comprises the step of administering an inhalation anaesthetic at sub-anaesthetic levels to the patient during an anaesthesia of the patient. A suitable agent may be methoxyflurane. | 12-15-2011 |
20120316247 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) - Disclosed herein is a method for administering compositions. Also disclosed are kits comprising a compound of formula (I) to (V), or an enantiomer, an analog, a derivative, an isomer, prodrug, or a pharmaceutically acceptable salt thereof, for use in temporal proximity to anesthesia. The methods, compositions and kits provided herein can be used for reducing anesthesia-induced neurotoxicity and post-operative cognitive dysfunction (POCD) in a subject. | 12-13-2012 |
20140066521 | ANITBACTERIAL OR PRESERVING COMPOSITION CONTAINING 3-BUTOXY-1,2-PROPANEDIOL - The present invention relates to an antibacterial and/or preserving composition which contains 3-butoxy-1,2-propanediol as a preserving agent. The antibacterial or preserving composition according to the present invention has an excellent resistance to microorganisms and has an excellent moisturizing effect, and hardly causes skin troubles. | 03-06-2014 |
20140142196 | METHOD OF KILLING BEDBUG EGGS - The present invention relates to a method of pre-rinsing laundry and treating other surfaces employing a composition that can kill bedbug eggs. The composition includes a fatty alcohol and an alcohol ethoxylate. | 05-22-2014 |
20140256828 | STABLE LIQUID FORMULATIONS OF VOLATILE GAS ANESTHETICS - A stable liquid nanoemulsion of a volatile gas anesthetic, such as, isoflurane or sevoflurane, is disclosed which is effective in inducing and maintaining a state of anesthesia and/or general anesthesia in a patent. A method of preparation of stable liquid formulations of volatile gas anesthetics is presented, as well as a method for directly testing the concentration of a volatile gas anesthetic in a stable liquid formulation. A kit comprising an amount of a stable liquid formulation of a volatile gas anesthetic, and the non-specialized equipment for administration of the same to a patient, either in an operating room environment or in the field, is also described herein. | 09-11-2014 |
20160022603 | NOVEL ANALGESIC COMPOSITIONS - The present invention provides compositions useful in reducing or preventing pain in a subject in need thereof. In certain embodiments, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration or periodic administration. | 01-28-2016 |
20160113887 | HALOGENATED ETHER COMPOUNDS AND METHODS OF INDUCING ANESTHESIA - A method of inducing anesthesia in a subject is provided. In some embodiments, the method provides administering to the subject via the respiratory system or via injection, an effective amount of a compound or a mixture of compounds selected from the group consisting of methyl-ethyl ethers, methyl-isopropyl ethers, and methyl-propyl ethers. | 04-28-2016 |
20170231924 | NOVEL ANALGESIC COMPOSITIONS | 08-17-2017 |
514723000 | Plural oxygens | 35 |
20080234390 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS - This invention relates to skin pore tighteners each of which comprises, as an active ingredient, a compound represented by the following formula: | 09-25-2008 |
20090124704 | Therapeutic foam - A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41 % of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein. | 05-14-2009 |
20090186949 | Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds - The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound bacterial signaling compounds produced by cells of a host containing a microbial pathogen. Methods for preventing and treating cell disorders, such as epithelial cell disorders including gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly, | 07-23-2009 |
20090239956 | LAMELLAR TYPE LIQUID CRYSTAL COMPOSITION FOR COSMETIC - Disclosed is a lamellar liquid crystal composition for cosmetic use, which contains one or more polyglycerol monoethers and has a lamellar liquid crystalline phase formed by the polyglycerol monoethers. The polyglycerol monoethers each have a hydrophile-lipophile balance (HLB) of 6 to 12 and are represented by following Formula (I): | 09-24-2009 |
20100016444 | Methods and Compositions for Treating Mammalian Nerve Tissue Injuries - To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury. | 01-21-2010 |
20100099778 | DEVICE AND METHOD FOR PRODUCING THERAPEUTIC FOAM - A device and a method for generating therapeutic foam from a sclerosing solution such as polidocanol and a gas which is absorbable or dissolvable in the body comprises a disposable cassette including a liquid container and a flexible chamber containing gas, chamber being formed as a loop. Located in the loop chamber is a foam generating mesh. In use, liquid is introduced into the chamber and then the cassette is inserted into a pumping machine where it is engaged by a peristaltic pump which circulates the contents of the loop chamber through the mesh, thus creating foam. When a steady state is reached, foam may be withdrawn using a syringe via either a port or septum. | 04-22-2010 |
20100190864 | Alkylene Oxide Derivative And Skin External Preparation Containing The Same - The present invention is to provide a new compound having a rough skin improving effect, excellent in safety, excellent in texture in use, especially free of sticky feeling, excellent in refreshing feeling, and capable to improve the base agent stability as a component. An alkylene oxide derivative is characterized by being represented by the below-described general formula (I): | 07-29-2010 |
20100249247 | ANTIMICROBIAL COMPOSITIONS - An antimicrobial composition for use as a disinfectant or a preservative. The disinfectant may be used in disinfecting and cleaning surfaces. The preservative is particularly useful in personal care and cosmetic products, and pharmaceuticals. The composition includes a base component and an alkyl mono propylene glycol ether, an alkyl mono glycerol ether, or a combination of these ethers. The base component may be water, alcohol, lotion, cream, shampoo, soap, cosmetic color agent, hair conditioner, lip balm, and face, eye or lip make up, ointment. | 09-30-2010 |
20100324150 | HYPERBRANCHED POLYGLYCEROL FOR IMPROVING HEART FUNCTION - A method of improving heart function in a subject, the method comprising administering an effective amount of a hyperbranched polyglycerol to a subject. The improvement in heart function may include one or more of an increase in myocardial contractile function, reduced or absent fibrosis, an increase in mechanical efficiency of the heart, an increase in ejection fraction, an increase in glucose oxidation or a decrease in fatty acid oxidation, as determined by conventional methods known in the art. | 12-23-2010 |
20110224307 | ANTIMICROBIAL COMPOSITIONS COMPRISING TRIMETHYLENE GLYCOL OLIGOMER AND METHODS OF USING THE COMPOSITIONS - Disclosed are antimicrobial compositions, and methods for killing, inhibiting, or preventing the growth of microbes, using trimethylene glycol oligomers or dimers. The trimethylene glycol oligomers and dimers have the formula R(CH | 09-15-2011 |
20110288180 | DIETARY PURGATIVES - Described are kits, food compositions and methods for cleaning the bowel, e.g., in preparation for a medical procedure, e.g., a diagnostic or treatment procedure, such as an endoscopic or surgical procedure, or radiologic imaging such as CT colography. | 11-24-2011 |
20120041074 | Method of inducing neovascularization - A method for inducing neovascularization in which a pharmaceutically effective amount of polyethylene glycol (PEG) is injected into the tissue of the subject for purposes of accelerating wound healing and mimicking age related macular degeneration, cancer, tumors, and atherosclerosis for further research purposes. | 02-16-2012 |
20130041041 | MICROWAVE REMEDIATION OF MEDICAL WASTES - Methods, devices, and remediation compositions for the microwave remediation of medical wastes are provided. The remediation compositions include a microwave active fluid including a microwave active liquid, a microwave enhancer, and a viscosity modifying agent. Methods include immersing medical waste in the remediation composition and then irradiating the medical waste and the remediation composition to remediate the medical waste. The devices include a container for the medical waste and the remediation composition, a microwave radiation source and a temperature monitoring device. | 02-14-2013 |
20130090389 | Polyethylene Glycol Compositions for Controlling Relapse of Herpes Labialis, Herpes Genitalis, and Herpes Zoster - The present invention pertains generally to the field of therapy, and more specifically to the field of therapy for herpes simplex and herpes zoster, and more particularly, to methods of reducing the rate of relapse, delaying relapse, and/or preventing relapse of herpes labialis (cold sores on the lips), herpes genitalis (genital herpes), and herpes zoster (shingles, zona), by topical administration of polyethylene glycol (PEG), or a composition comprising PEG. | 04-11-2013 |
20130225692 | FORMULATIONS COMPRISING POLYETHYLENE GLYCOL - The present invention concerns a solid formulation for oral administration as a solid comprising polyethylene glycol and a further solid such as mannitol. The formulation may be used to prevent gastrointestinal disorders such as constipation in healthy subjects. In some embodiments, the solid formulation is chewable or suckable. | 08-29-2013 |
20130231397 | SYNERGISTIC PREPARATIONS BASED ON MIXTURES OF GLYCEROL ETHER WITH AROMATIC ALCOHOL FOR CONTROLLING MYCOBACTERIA - A method of preserving a cosmetic product by adding to the cosmetic product a concentrate, which may be in anhydrous form, which includes (a) 1-(2-ethylhexyl) glycerol ether, and (b) one or more aromatic alcohols, (a) and (b) having a weight ratio of (a)/(b) is less than or equal to 0.15. | 09-05-2013 |
20130267607 | LAXATIVE GEL COMPOSITION - An edible, gel composition of a PEG and a gel forming agent wherein the composition is prepared by mixing together the PEG with gel forming agent to form the edible gel composition, and the edible gel composition has laxative properties. | 10-10-2013 |
20130267608 | SOLID, EDIBLE, CHEWABLE LAXATIVE COMPOSITION - An edible, solid composition comprising a laxative and one or more bulking agents in aqueous media wherein the laxative is polyethylene glycol and the composition is prepared by dissolving the polyethylene glycol in aqueous media together with one or more bulking agents and subjecting the mixture to heat up to at least about 100° C. | 10-10-2013 |
20130289129 | RADIATION CURABLE COATING COMPOSITION CONTAINING LOW MOLECULAR WEIGHT POLYTRIMETHYLENE ETHER GLYCOL - The present disclosure is directed to a radiation curable coating composition comprising low molecular weight polytrimethylene ether glycol. This disclosure is further directed to an antimicrobial coating layer formed from the coating composition comprising low molecular weight polytrimethylene ether glycol. The coating compositions can be used as interior and exterior top coats, basecoats, primers, primer surfacers and primer fillers. The disclosure is particularly directed to a coating composition comprising components derived from renewable resources. | 10-31-2013 |
20130345314 | Compositions and methods for treating a damaged cardiovascular element - In the present invention, the applicants describe methods and compositions of treating damaged cardiovascular elements and cardiovascular conditions including hypotension, atherosclerotic lesions, vulnerable plaque, and acute myocardial infarct. The applicants demonstrate the ability of a biomembrane sealing agent to accumulate on the walls of damaged blood vessels and help improving mean arterial pressure following tissue injury. The applicants describe the use of formulations comprising at least one biomembrane sealing agent and one bioactive agent for prophylactic treatment such as they could be administered concurrently to an invasive therapeutic intervention or after the insult (i.e. post-injury or post-surgery). Alternatively, these methods and compositions could be used to reduce the severity of cardiovascular diseases after onset. | 12-26-2013 |
20140005273 | GLYCERIN ETHER ETHOXYLATE SOLFACTANTS | 01-02-2014 |
20140039066 | FORMULATION FOR GRITTY FOAM DISPENSER - Disclosed herein are foamable gritty foam compositions that can suspend particulate mechanical scrubbers with particles sized from about 100 microns to about 800 microns that is capable of being foamed through a non-aerosol, or unpressurized pump dispenser. | 02-06-2014 |
20140057993 | Prophylaxis and Treatment of Enteropathogenic Bacterial Infection - In accordance with the present invention, methods are provided for the prevention and/or treatment of enteropathogenic bacterial infection in the gastrointestinal tract of a subject, and the diarrhea associated with the infection, by administration to the subject of a low molecular weight polyethylene glycol, as well concurrent administration with other antibiotic and antidiarrheal agents. Methods for reduction or suppression of inflammation, and inhibition of β1-integrin expression in the gastrointestinal mucosa are also provided. Also described is a kit suitable for use with the methods disclosed. | 02-27-2014 |
20140080918 | THERAPEUTIC SOLUTION CONCENTRATE - A concentrated poly(ethylene glycol) solution that has good stability for extended storage is provided for use as a laxative. The concentrated solution comprises water, sodium benzoate, poly(ethylene glycol), and enough acid to yield a solution having a pH at 25° C. in the range 3.0-5.0. It is prepared and packaged to minimize the accumulation of degradation products. | 03-20-2014 |
20140100289 | METHODS AND COMPOSITIONS FOR TREATING MAMMALIAN NERVE TISSUE INJURIES - To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury. | 04-10-2014 |
20140107224 | GENERATION OF THERAPEUTIC MICROFOAM - Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen. | 04-17-2014 |
20140221501 | THERAPEUTIC FOAM - A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed. | 08-07-2014 |
20140235730 | SOLID, EDIBLE, CHEWABLE LAXATIVE COMPOSITION - The invention is directed to an edible solid composition having laxative properties. The composition has a smooth mouth feel, in non-gritty and has a pleasant taste. It is prepared by melt-combining together the ingredients including a bulking agent and laxative as well as an optional flavor agent and electrolyte. The melt is a dispersion containing a substantially homogeneous combination of ingredients. The melt is cooled to form an amorphous solid dispersion or solution of the ingredients. The ingredients are mutually compatible so that upon cooling they do not separately crystallize to form a gritty mouth feel product. | 08-21-2014 |
20140316010 | COMPOSITION FOR THE TREATMENT OF DANDRUFF - A composition for treating dandruff is provided. The composition includes glycerol with a concentration of not larger than 10 wt %, a second, low molecular weight polyol with a concentration of not larger than 10 wt %, and a saline solution. The composition is free of chemical surfactants, antiseptics, or foaming agents and the like, which may cause allergic or hypersensitive conditions, and has the advantages of simple constituents, low cost, and effective outcomes on the treatment of dandruff. Long-term application of the composition on the scalp is therefore suggested. | 10-23-2014 |
20140343168 | GLYCERIN ETHER ETHOXYLATE SOLFACTANTS - The present invention relates to novel glycerin ether ethoxylate solfactant compounds, compositions employing the same, and methods of using these compounds. Beneficially the compounds have efficacy as both solvents and surfactants with low foam and low viscosity. The compounds of the present invention can be used as antimicrobials and/or sanitizing agents in various formulations. The compounds of the present invention are also suitable for use as solvents and/or hydrotropes. | 11-20-2014 |
20140357726 | USE OF PEGYLATED ALCOHOLS FOR THE TREATMENT OF ACTINIC KERATOSIS - Use of pegylated alcohols for the treatment of actinic keratosis. | 12-04-2014 |
20150306046 | FOODS, SYSTEMS, METHODS, AND KITS FOR PROVIDING ELECTROLYTE REPLACEMENT - Described herein are methods, compositions, systems, and kits that effectively deliver a laxative to a patient along with effective electrolyte replenishment by delivering both a laxative and electrolytes via a food item. The food item is prepared by either combining, mixing, or integrating the ingredients that form the food item together with one of or both of a laxative and electrolytes so that the ingredients in the food item either eliminate or significantly reduce the poor taste associated with either the electrolytes or the laxative. Eliminating or reducing the poor taste associated with either electrolytes or laxative, greatly improves patient satisfaction and compliance with ingesting these substances in order to, for example, prepare the GI tract of the patient for a medical or surgical procedure. | 10-29-2015 |
20160009619 | POLYGLYCERIN DIALKYL OR ALKENYL ETHER, AND COSMETIC COMPOSITION CONTAINING SAME | 01-14-2016 |
20160113888 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER - An object of the present invention is to provide a novel drug for treating cancer. The present invention relates to a pharmaceutical composition for treating or preventing cancer which comprises, as an active ingredient, a triethylene glycol of the following formula (I) or a derivative thereof: | 04-28-2016 |
20160193245 | FORMULATIONS COMPRISING POLYETHYLENE GLYCOL | 07-07-2016 |